Literature DB >> 24861846

Systematic review of the economic value of diarrheal vaccines.

Richard Rheingans1, Mirna Amaya2, John D Anderson3, Poulomy Chakraborty3, Jacob Atem3.   

Abstract

Diarrheal disease is a leading cause of child mortality in low-income settings and morbidity across a range of settings. A growing number of studies have addressed the economic value of new and emerging vaccines to reduce this threat. We conducted a systematic review to assess the economic value of diarrheal vaccines targeting a range of pathogens in different settings. The majority of studies focused on the economic value of rotavirus vaccines in different settings, with most of these concluding that vaccination would provide significant economic benefits across a range of vaccine prices. There is also evidence of the economic benefits of cholera vaccines in specific contexts. For other potential diarrheal vaccines data are limited and often hypothetical. Across all target pathogens and contexts, the evidence of economic value focuses the short-term health and economic gains. Additional information is needed on the broader social and long-term economic value of diarrhea vaccines.

Entities:  

Keywords:  cost-effectiveness; diarrhea; economic; enteric; vaccine; value

Mesh:

Substances:

Year:  2014        PMID: 24861846      PMCID: PMC5396238          DOI: 10.4161/hv.29352

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  122 in total

1.  Distributional impact of rotavirus vaccination in 25 GAVI countries: estimating disparities in benefits and cost-effectiveness.

Authors:  Richard Rheingans; Deborah Atherly; John Anderson
Journal:  Vaccine       Date:  2012-04-27       Impact factor: 3.641

Review 2.  Do we fully understand the economic value of vaccines?

Authors:  Michael Drummond; Catherine Chevat; Mickael Lothgren
Journal:  Vaccine       Date:  2007-05-15       Impact factor: 3.641

3.  Fiscal consequences of changes in morbidity and mortality attributed to rotavirus immunisation.

Authors:  Nikolaos Kotsopoulos; Mark P Connolly; Maarten J Postma; Raymond C W Hutubessy
Journal:  Vaccine       Date:  2013-09-18       Impact factor: 3.641

4.  Cost-effectiveness of a new rotavirus vaccination program in Pakistan: a decision tree model.

Authors:  Hiten D Patel; Eric T Roberts; Dagna O Constenla
Journal:  Vaccine       Date:  2013-10-29       Impact factor: 3.641

5.  Cost-effectiveness of rotavirus vaccination in Bolivia from the state perspective.

Authors:  Emily R Smith; Emily E Rowlinson; Volga Iniguez; Kizee A Etienne; Rosario Rivera; Nataniel Mamani; Rick Rheingans; Maritza Patzi; Percy Halkyer; Juan S Leon
Journal:  Vaccine       Date:  2011-09-02       Impact factor: 3.641

6.  Budget impact and cost-effectiveness of including a pentavalent rotavirus vaccine in the New Zealand childhood immunization schedule.

Authors:  Richard J Milne; Keith Grimwood
Journal:  Value Health       Date:  2009-03-18       Impact factor: 5.725

7.  Impact of transmission dynamics on the cost-effectiveness of rotavirus vaccination.

Authors:  Eunha Shim; Alison P Galvani
Journal:  Vaccine       Date:  2009-05-03       Impact factor: 3.641

8.  A cost effectiveness and capacity analysis for the introduction of universal rotavirus vaccination in Kenya: comparison between Rotarix and RotaTeq vaccines.

Authors:  Albert Jan van Hoek; Mwanajuma Ngama; Amina Ismail; Jane Chuma; Samuel Cheburet; David Mutonga; Tatu Kamau; D James Nokes
Journal:  PLoS One       Date:  2012-10-24       Impact factor: 3.240

9.  Pathogen-specific risk of chronic gastrointestinal disorders following bacterial causes of foodborne illness.

Authors:  Chad K Porter; Daniel Choi; Brooks Cash; Mark Pimentel; Joseph Murray; Larissa May; Mark S Riddle
Journal:  BMC Gastroenterol       Date:  2013-03-08       Impact factor: 3.067

Review 10.  Enteric pathogens and reactive arthritis: a systematic review of Campylobacter, salmonella and Shigella-associated reactive arthritis.

Authors:  Anuli N Ajene; Christa L Fischer Walker; Robert E Black
Journal:  J Health Popul Nutr       Date:  2013-09       Impact factor: 2.000

View more
  10 in total

1.  Current issues and priorities in childhood nutrition, growth, and infections.

Authors:  Rehana A Salam; Jai K Das; Zulfiqar A Bhutta
Journal:  J Nutr       Date:  2015-04-01       Impact factor: 4.798

Review 2.  The Value(s) of Vaccination: Building the Scientific Evidence According to a Value-Based Healthcare Approach.

Authors:  Giovanna Elisa Calabro'; Elettra Carini; Alessia Tognetto; Irene Giacchetta; Ester Bonanno; Marco Mariani; Walter Ricciardi; Chiara de Waure
Journal:  Front Public Health       Date:  2022-03-09

3.  Global economic evaluation of oral cholera vaccine: A systematic review.

Authors:  Siew Li Teoh; Surachai Kotirum; Raymond C W Hutubessy; Nathorn Chaiyakunapruk
Journal:  Hum Vaccin Immunother       Date:  2017-12-15       Impact factor: 3.452

4.  Cost-Effectiveness of Monovalent Rotavirus Vaccination of Infants in Malawi: A Postintroduction Analysis Using Individual Patient-Level Costing Data.

Authors:  Naor Bar-Zeev; Jacqueline E Tate; Clint Pecenka; Jean Chikafa; Hazzie Mvula; Richard Wachepa; Charles Mwansambo; Themba Mhango; Geoffrey Chirwa; Amelia C Crampin; Umesh D Parashar; Anthony Costello; Robert S Heyderman; Neil French; Deborah Atherly; Nigel A Cunliffe
Journal:  Clin Infect Dis       Date:  2016-05-01       Impact factor: 9.079

Review 5.  Accounting for equity considerations in cost-effectiveness analysis: a systematic review of rotavirus vaccine in low- and middle-income countries.

Authors:  Marie-Anne Boujaoude; Andrew J Mirelman; Kim Dalziel; Natalie Carvalho
Journal:  Cost Eff Resour Alloc       Date:  2018-05-18

Review 6.  Experiences with rotavirus vaccines: can we improve rotavirus vaccine impact in developing countries?

Authors:  A D Steele; J C Victor; M E Carey; J E Tate; D E Atherly; C Pecenka; Z Diaz; U D Parashar; C D Kirkwood
Journal:  Hum Vaccin Immunother       Date:  2019-02-08       Impact factor: 3.452

7.  Re-evaluating the potential impact and cost-effectiveness of rotavirus vaccination in 73 Gavi countries: a modelling study.

Authors:  Frédéric Debellut; Andrew Clark; Clint Pecenka; Jacqueline Tate; Ranju Baral; Colin Sanderson; Umesh Parashar; Laura Kallen; Deborah Atherly
Journal:  Lancet Glob Health       Date:  2019-12       Impact factor: 26.763

Review 8.  Herd Immunity Effects in Cost-Effectiveness Analyses among Low- and Middle-Income Countries.

Authors:  Siyu Ma; Tara A Lavelle; Daniel A Ollendorf; Pei-Jung Lin
Journal:  Appl Health Econ Health Policy       Date:  2022-01-10       Impact factor: 3.686

9.  Reaching every child with rotavirus vaccine: Report from the 10th African rotavirus symposium held in Bamako, Mali.

Authors:  Samba O Sow; A Duncan Steele; Jason M Mwenda; George E Armah; Kathleen M Neuzil
Journal:  Vaccine       Date:  2017-10-09       Impact factor: 3.641

10.  Capturing Budget Impact Considerations Within Economic Evaluations: A Systematic Review of Economic Evaluations of Rotavirus Vaccine in Low- and Middle-Income Countries and a Proposed Assessment Framework.

Authors:  Natalie Carvalho; Mark Jit; Sarah Cox; Joanne Yoong; Raymond C W Hutubessy
Journal:  Pharmacoeconomics       Date:  2018-01       Impact factor: 4.981

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.